What's Happening?
Vietnam Vaccine Joint Stock Company (VNVC) and French pharmaceutical company Sanofi have advanced their partnership to localize vaccine manufacturing in Vietnam. This development was announced during the Vietnam-France High-Level Conference held in Hanoi,
organized by Vietnam's Ministry of Health and the French Embassy. The partnership aims to strengthen Vietnam's domestic vaccine manufacturing capabilities, ensuring a stable supply for the National Immunization Program and supporting Vietnam's ambition to become a regional hub for vaccine manufacturing and innovation. The conference highlighted the importance of self-sufficiency in vaccine research, manufacturing, and supply as a critical pillar for public health and economic growth. The VNVC Vaccine and Biological Manufacturing Plant, with an initial investment of over VND2.5 trillion, is expected to begin operations by the end of 2027, with production targeted for 2028.
Why It's Important?
The partnership between VNVC and Sanofi is significant as it aims to enhance Vietnam's vaccine manufacturing capabilities, which is crucial for national health security and economic growth. By localizing vaccine production, Vietnam can reduce dependency on foreign imports and ensure a stable supply for its immunization programs. This move is expected to strengthen Vietnam's position in the global biotechnology value chain and support its long-term ambition of becoming a regional hub for vaccine manufacturing and innovation. The collaboration also highlights the importance of international partnerships in advancing healthcare technologies and addressing future healthcare challenges.
What's Next?
The VNVC Vaccine and Biological Manufacturing Plant is expected to begin operations by the end of 2027, with the first vaccine batches produced in Vietnam anticipated in 2028. The partnership will focus on localizing the manufacturing of high-demand vaccines for children and adults, with Sanofi providing guidance on manufacturing technology, production processes, quality management systems, and workforce training. The collaboration is expected to accelerate research, technology transfer, and vaccine manufacturing in Vietnam, contributing to the country's vaccine self-sufficiency and strengthening national health security.
